Then it becomes a done deal, because that's what Abbvie offered to buy Allergan at. (78.45 X .866 + 120.30= 189.00) or there about.
The deal is cash and stock. The stock portion of the transaction is based on a value of $78.45, which is the value Abbvie closed at on June 24th when the agreement was reached. Getting to that number has no relevance to the deal closing. If Abbvie stock is at $78.45 when they close, then it's a dollar for dollar wash. If the stock goes up, Abbvie is getting a better deal because the purchase could have been based off that higher price. If the stock goes down, Abbvie is losing money to the shareholders. Whenever stock is part of the purchase transaction, there's going to be some variance at closing. It's normal and not relevant to whether or not the deal goes through or when it goes through.
There’s no IF involved with ABBV stock. It’s down and STAYING in high $60s and low $70s Abbvie Shareholders got nailed good. We need a big layoff IF this deal closes.
